Aprea Therapeutics公司近日公布了其Wee1抑制剂候选药物Apr-1051的最新积极临床数据。在正在进行的ACESOT-1051临床试验中,研究观察到了额外的临床活性信号,其中包括第二例达到部分缓解(Partial Response)的病例。这一进展进一步支持了Apr-1051在目标患者群体中的治疗潜力。
Aprea Therapeutics公司近日公布了其Wee1抑制剂候选药物Apr-1051的最新积极临床数据。在正在进行的ACESOT-1051临床试验中,研究观察到了额外的临床活性信号,其中包括第二例达到部分缓解(Partial Response)的病例。这一进展进一步支持了Apr-1051在目标患者群体中的治疗潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.